Former Chief Executive Officer & Director, Kenvue
Search every verified Thibaut Mongon interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Thibaut Mongon, as CEO of Kenvue, has discussed the company’s performance and strategy following its spin-off from Johnson & Johnson in May 2023. In earnings calls and media appearances, Mongon described 2023 as a “transformational” year and highlighted the company’s financial results, including $4 billion in revenue and 7.7% organic growth in the second quarter, which he called one of the strongest quarters in the company’s history. He noted that the company maintained its guidance for the full year but tightened the range to reflect a softer start to the cold and flu season. Mongon also addressed a class action lawsuit related to the efficacy of a product, stating that the company saw no impact to the business and that the FDA had not made any determination on the matter. Mongon outlined three key priorities for 2024: reaching more consumers by focusing on 15 priority brands, freeing up resources to invest in those brands, and fostering a culture that rewards performance and impact. He acknowledged challenges in the U.S. skin health and beauty segment, particularly with the Neutrogena brand, and said that restoring its growth was a priority. Mongon also discussed the company’s employee well-being initiatives, including a global employee assistance program and a “global care day” for employees. He expressed confidence in the company’s business model and portfolio, stating that Kenvue was focused on fundamentals and building a strong foundation as an independent company.
“2023 was a year of transformational change for our company and for 22,000 Kenvue employees around the world — our teams accomplished a tremendous amount, successfully standing up Kenvue as an independent public company while continuing to drive profitable growth.”
“As we enter 2024 we have identified three key priorities that will enable our continued transition as an independent company while continuing to grow the business: reach more consumers with a stronger focus on our 15 priority brands, free up resources to invest behind our brands and foster a culture that rewards perfor...”
“In 2023 we delivered on a long‑term value creation algorithm centered around profitable growth, durable cash flow generation and disciplined capital allocation, and we achieved about 5% organic growth.”
“Restoring Neutrogena to the level of growth we know the brand is capable of is a priority for me and for the team — we must improve our in‑store executional capabilities to drive stronger demand, better communicate our value proposition, launch innovation successfully and support our brands with a robust level of marke...”
“The North America skin health and beauty leadership team is taking action in three areas: strengthen in‑store presence and prominence, enhance consumer engagement through distinct and consistent brand experiences supported by revamped marketing, and amplify innovations to bolster demand with consumers and healthcare pr...”
“We continued our multi‑year program to expand gross margins in 2023 with 30 basis points of expansion through thoughtful revenue management initiatives and relentless supply chain optimization, demonstrating we can drive profitable growth even in a dynamic and uncertain macro backdrop.”
“We utilized our strong free cash flow to initiate our dividend program, delivering on our commitment of returning cash to shareholders.”
“As we exit our transition services agreements with Johnson & Johnson, we are not simply replicating legacy processes but intentionally reinventing our ways of working — implementing modern systems designed specifically to meet the needs of our new company and enable speed, agility, accuracy and a lower cost base.”
“In 2024 we are deploying our new Kenvue Performance Management plan with clear goals and a heightened sense of accountability, introducing incentive programs for leaders that reward impact on the four drivers of shareholder return: topline growth, margin expansion, earnings growth and free cash flow.”
“We're confident we have correctly diagnosed our weaknesses and are making the necessary changes; recovery in the US skin business will not be overnight but we expect the actions we are taking to generate impact in the second half of the year.”
“We had a healthy quarter in Q3 with $3.9 billion in revenue, 3.6% growth on top of 4.7% growth last year — that shows the power of the portfolio we have at Kenvue and the strength of our model.”
“We announce another 20 cent dividend per share payable in November — pleased with our results and confident in our future.”
“We have maintained the base of our guidance for the full year but tightened it to reflect a soft start of the cold and flu season; we see other parts of the portfolio doing very well.”
“We continue to build our company as a fit-for-purpose standalone company focused on the consumer — we are on track with a program moving into the future and will continue to focus on what we've done for 135 years: being close to consumers and bringing them products and solutions they need.”
“We just launched a new Motrin Dual Action that puts together ingredients from two iconic brands and it has been very well received by consumers in the U.S.”
Kenvue (KVUE) announced on Thursday it would cut its annual profit forecast after seeing a weakening demand for cold and flu ...
Kenvue CEO Thibaut Mongon joins ‘Squawk on the Street’ to discuss the company's latest quarter, their new products in the market, and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn:…
CEO, Kenvue Thibaut Mongon lends his voice to the CEO video series for the #WellbeingAtWork campaign where C-suite level ...
Yahoo Finance health care reporter Anjalee Khemlani spoke with Kenvue CEO Thibaut Mongon about the company's latest ...
Thibaut Mongon, Kenvue CEO, joins 'Squawk on the Street' to discuss the company's quarterly earnings results, what Mongon is seeing from the consumer, and much more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com…
#Kenvue #youtube #stockmarket Kenvue CEO Thibaut Mongon joins Yahoo Finance's Anjalee Khemlani on the floor of the New York Stock Exchange to discuss the IPO of the Johnson & Johnson spinoff and the company's outlook in the personal pharmaceutical space. Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get t…
El Dr. Thibaut Mongon, Gerente regional de Johnson & Johnson Vision Care para America Latina, habló en exclusiva con ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Thibaut Mongon.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →